Configuration of crosslinked multi-polymeric multi-units for site-specific delivery of nicotine

Abstract

Parkinson’s Disease (PD) is a progressively debilitating neurodegenerative disease that affects the central nervous system and leads to severe difficulties with body movements. PD occurs due to the selective degeneration of neurons in the region of the brain known as the substantia nigra pars compacta. To date PD remains an incurable disease. Currently prescribed drugs provide only symptomatic relief to patients. Furthermore, they have considerable side effects and are often ineffective in the later stages of the disease or need to be used in combination in order to be effective. The role of neuroprotectants as a preventative measure in PD therapy is consequently receiving a great deal of attention and is being subjected to extensive research. This study sought to develop a novel prolonged-release drug delivery device for providing site-specific administration of newly researched neuroprotective agents. Nicotine was employed as the model neuroprotectant to incorporate in a novel reinforced crosslinked multiple-unit multi-polymeric drug delivery device. The study was the first of its kind to develop and employ the alkaloid for this purpose in a formulated delivery system. The device was intended to be one that provided zero-order prolonged release of the drug over a period of 1-2 months. The device was formulated such that its design was in keeping with the potential for implantation into the substantia nigra pars compacta to provide site-specific drug delivery. In order to do so, polymers, with biocompatible and bioerodable characteristics were selected to incorporate the drug within a reinforced crosslinked matrix. The study elucidated the mechanism of crosslinking of ionotropically crosslinked alginate spheres (gelispheres) with a variety of crosslinking agents through an evaluation of physicomechanical properties of the crosslinked system. The presence of barium in the crosslinked matrices generated densely networked gelispheres which retained their robustness following exposure to hydrating media and displayed promising potential for 4 entrapping drug molecules and retarding their release. The system was reinforced employing hydroxyethylcellulose (HEC) and polyacrylic acid (PAA). A Design of Experiments approach employing a Plackett-Burman screening design enabled optimisation of the proposed device in terms of reinforcing polymers (HEC and PAA) and crosslinking agents (barium and calcium). In order to further attenuate drug release rate the optimised crosslinked gelispheres were exposed to dilute hydrochloric acid (HCl) which significantly decreased gelisphere matrix swelling and erosion following exposure to simulated cerebrospinal fluid (CSF). These gelispheres were thereafter incorporated into a compressed release-rate modulating polymeric discs. Zero-order drug release was observed for a period of 50 days in simulated CSF when the optimised gelispheres were incorporated into compressed poly(lactic-co-glycolic) acid (PLGA) discs. Alternative approaches to modify drug release kinetics were also evaluated including the use of PLGA coatings on compressed hydroxypropylmethylcellulose-polyethylene oxide (HPMC-PEO) discs incorporating gelispheres and the use of crosslinked alginate-pectinate gelispheres as carrier systems to deliver PLGA-PLA (polylactic acid) microparticles incorporating drug. A Box-Behnken statistical design was employed to formulate and optimise the drug carrying PLGA-PLA microparticles. In both of the abovementioned cases we obtained sustained zeroorder drug release.